1. A National Registry of Thalassemia in Turkey: Demographic and Disease Characteristics of Patients, Achievements, and Challenges in Prevention
- Author
-
Talia Ileri, Yesim Aydinok, Ezgi Paslı Uysalol, Aydan Akdeniz, Mustafa Buyukavci, Naci Tiftik, Mehmet Akin, Berna Atabay, Akif Yesilipek, Yeşim Oymak, Turkan Patiroglu, Güçhan Alanoğlu, Arzu Akcay, Özcan Bör, Canan Vergin, Gonul Aydogan, Hüseyin Tokgöz, Sule Unal, Zeynep Karakas, Adalet Meral Güneş, Nur Soyer, Meral Türker, Elif Güler Kazanci, Mediha Akcan, Banu Oflaz, Nihal Karadaş, Selda Kahraman, Yurdanur Kilinç, Murat Söker, Süheyla Ocak, Melike Sezgin Evim, Didem Atay, Selma Unal, Umran Caliskan, Ali Bay, E. Unal, and Ege Üniversitesi
- Subjects
Male ,lcsh:Internal medicine ,Pediatrics ,medicine.medical_specialty ,Turkey ,Thalassemia ,β ,Management of thalassemia ,Prenatal diagnosis ,β-thalassemia mutations ,03 medical and health sciences ,Age Distribution ,0302 clinical medicine ,medicine ,Humans ,Mass Screening ,Registries ,lcsh:RC31-1245 ,Alleles ,Demography ,Cause of death ,beta-thalassemia mutations ,Iron chelators ,thalassemia mutations ,lcsh:RC633-647.5 ,business.industry ,Deferasirox ,lcsh:Diseases of the blood and blood-forming organs ,Hematology ,medicine.disease ,Hemoglobinopathies ,Transplantation ,Phenotype ,Hemoglobinopathy ,Population Surveillance ,030220 oncology & carcinogenesis ,Mutation ,Cohort ,Splenectomy ,Female ,business ,Research Article ,030215 immunology ,medicine.drug - Abstract
WOS: 000426572200002, PubMed ID: 28404539, Objective: The Turkish Society of Pediatric Hematology set up a National Hemoglobinopathy Registry to demonstrate the demographic and disease characteristics of patients and assess the efficacy of a hemoglobinopathy control program (HCP) over 10 years in Turkey. Materials and Methods: A total of 2046 patients from 27 thalassemia centers were registered, of which 1988 were eligible for analysis. This cohort mainly comprised patients with beta-thalassemia major (n = 1658, 83.4%) and intermedia (n = 215, 10.8%). Results: The majority of patients were from the coastal areas of Turkey. The high number of patients in Southeastern Anatolia was due to that area having the highest rates of consanguineous marriage and fertility. The most common 11 mutations represented 90% of all beta-thalassemia alleles and 47% of those were IVS1-110(G->A) mutations. The probability of undergoing splenectomy within the first 10 years of life was 20%, a rate unchanged since the 1980s. Iron chelators were administered as monotherapy regimens in 95% of patients and deferasirox was prescribed in 81.3% of those cases. Deferasirox administration was the highest (93.6%) in patients aged, Ege Children's Foundation; Novartis Pharmaceuticals CorporationNovartis, The authors thank Caglar Serdar, Aylin Gokduman, and Tolga Turgay of Plexus Information Technologies for their website support. The current study and the work presented here are from an Investigator Initiated Trial, which was sponsored by the Ege Children's Foundation and funded by Novartis Pharmaceuticals Corporation.
- Published
- 2018
- Full Text
- View/download PDF